SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq: MEND) today announced that positive data from two clinical studies evaluating the use of the Micrus Endovascular Cerecyte® bioactive microcoil in the treatment of cerebral aneurysms have been published in peer-reviewed scientific journals. Cerecyte platinum microcoils contain a polyglycolic acid filament that researchers suggest may accelerate the healing process.
